Cardiovascular Flashcards
Amlodipine
Mechanism
- L-type calcium channel blocker
- Reduces cardiac and smooth muscle contractility
Vascular smooth muscle
- amlodipine = nifedipine > diltiazem > verapamil
Cardiac muscle
- verapamil > diltiazem > amlodipine = nifedipine
Clevedipine
Mechanism
- L-type calcium channel blocker
- Reduces cardiac and smooth muscle contractility
Vascular smooth muscle
- amlodipine = nifedipine > diltiazem > verapamil
Cardiac muscle
- verapamil > diltiazem > amlodipine = nifedipine
Nicardipine
Mechanism
- L-type calcium channel blocker
- Reduces cardiac and smooth muscle contractility
Vascular smooth muscle
- amlodipine = nifedipine > diltiazem > verapamil
Cardiac muscle
- verapamil > diltiazem > amlodipine = nifedipine
Nifedipine
Mechanism
- L-type calcium channel blocker
- Reduces cardiac and smooth muscle contractility
Vascular smooth muscle
- amlodipine = nifedipine > diltiazem > verapamil
Cardiac muscle
- verapamil > diltiazem > amlodipine = nifedipine
Nimodipine
Mechanism
- L-type calcium channel blocker
- Reduces cardiac and smooth muscle contractility
Vascular smooth muscle
- amlodipine = nifedipine > diltiazem > verapamil
Cardiac muscle
- verapamil > diltiazem > amlodipine = nifedipine
Dihydropyridines
Site of action
Drug list
- Act on vascular smooth muscle
- Amlodipine, clevidipine, nicardipine, nifedipine, nimodipine
Non-dihydropyridines
Site of action
Drug list
- Act on cardiac muscle
- Diltiazem, verapamil
Drug class
- Act on vascular smooth muscle
- Amlodipine, clevidipine, nicardipine, nifedipine, nimodipine
Dihydropyridines
Calcium channel blockers
Drug class
- Act on cardiac muscle
- Diltiazem, verapamil
Non-dihydropyridines
Calcium Channel Blockers
Amlodipine
Clinical Use
- Hypertension
- Angina (including Prinzmetal)
- Raynaud phenominon
Clevidipine
Clinical Use
- Hypertensive urgency/emergency
- Angina (including Prinzmetal)
- Raynaud phenominon
Nicardipine
Clinical Use
- Hypertension
- Angina (including Prinzmetal)
- Raynaud Phenomenon
Nifedipine
Clinical Use
- Hypertension
- Angina (including Prinzmetal)
- Raynaud’s Phenomenon
Nimodipine
Clinical Use
- Subarachnoid hemorrhage
- Prevents cerebral vasospasm
Diltiazem
Clinical Use
- Hypertension
- Angina
- A. Fib/Flutter
Verapamil
Clinical Use
- Hypertension
- Angina
- A.Fib/flutter
Amlodipine
Toxicity
- Cardiac Depression
- AV Block
- Peripheral edema
- Flushing
- Dizziness
- Constipation
- Gingival hyperplasia
Clevidipine
Toxicity
- Cardiac Depression
- AV Block
- Peripheral edema
- Flushing
- Dizziness
- Constipation
- Gingival hyperplasia
Nicardipine
Toxicity
- Cardiac Depression
- AV Block
- Peripheral edema
- Flushing
- Dizziness
- Constipation
- Gingival hyperplasia
Nifedipine
Toxicity
- Cardiac Depression
- AV Block
- Peripheral edema
- Flushing
- Dizziness
- Constipation
- Gingival hyperplasia
Nimodipine
Toxicity
- Cardiac Depression
- AV Block
- Peripheral edema
- Flushing
- Dizziness
- Constipation
- Gingival hyperplasia
Diltazem
Toxicity
- Cardiac Depression
- Peripheral edema
- Flushing
- Dizziness
- Constipation
- Gingival hyperplasia
Verapamil
Toxicity
- Cardiac Depression
- Peripheral edema
- Hyperprolactinemia
- Flushing
- Dizziness
- Constipation
- Gingival hyperplasia
Hydralazine
Mechanism of action
- î cGMP ⇒ smooth vessel relaxation
- vasodilates arterioles > veins
- Reduces Afterload
Hydralazine
Clinical Use
- Severe Hypertension (especially acute)
- HF (w/ organic nitrate)
- Safe for Pregnancy
- co-admin w/ beta-blocker to prevent reflex tachycardia
Hydralazine
Toxicity
- Compensatory tachycardia
- Fluid retention
- Headache
- Angina
- Lupus-like symptoms
- Contraindicated in angina/CAD
Nitroprusside
Mechanism
- Î cGMP via direct release of NO
Nitroprusside
Clinical Use
- Hypertensive Emergency
Nitrprusside
Toxicity
- Cyanide Toxicity
Fenoldopam
Mechanism
- Dopamine D1 receptor agonist
- Increased naturesis
- reduced BP
Fenoldapam
Clinical Use
- Hypertensive Emergency
- coronary, peripheral, renal, splanchnic vasodilation
Fenoldapam
Toxicity
- Reflex tachycardia
- hypotension
Nitroglycerine
Mechanism
- Vasodilation by increased NO of in vasc smooth muscle
- ⇒ ^^ cGMP and smooth muscle relaxation
- Dilate veins >> arteries
- reduces preload
Isosorbide dinitrate
Mechanism
- Vasodilation by increased NO of in vasc smooth muscle
- ⇒ ^^ cGMP and smooth muscle relaxation
- Dilate veins >> arteries
- reduces preload
Isosorbide mononitrate
Mechanism
- Vasodilation by increased NO of in vasc smooth muscle
- ⇒ ^^ cGMP and smooth muscle relaxation
- Dilate veins >> arteries
- reduces preload
Nitroglycerine
Clinical Use
- Angina
- Acute Coronary Syndrome
- Pulmonary Edema
Isosorbide dinitrate
Clinical Use
- Angina
- Acute Coronary Syndrome
- Pulmonary Edema
Isosorbide mononitrate
Clinical Use
- Angina
- Acute Coronary Syndrome
- Pulmonary Edema
Nitroglycerine
Toxicity
- Reflex Tacycardia (tx w/ Beta-blockers)
- Hypotension
- flushing
- Headache
- “Monday disease”
- in industrial exposure; tolerance for vasodilation of actionduring work week
- loss of tolerance over the weekend
- ⇒ tachycardia, dizziness, headache on re-exposure
Isosorbide Dinitrate
Toxicity
- Reflex Tacycardia (tx w/ Beta-blockers)
- Hypotension
- flushing
- Headache
- “Monday disease”
- in industrial exposure; tolerance for vasodilation of actionduring work week
- loss of tolerance over the weekend
- ⇒ tachycardia, dizziness, headache on re-exposure
Isosorbide Mononitrate
Toxicity
- Reflex Tacycardia (tx w/ Beta-blockers)
- Hypotension
- flushing
- Headache
- “Monday disease”
- in industrial exposure; tolerance for vasodilation of actionduring work week
- loss of tolerance over the weekend
- ⇒ tachycardia, dizziness, headache on re-exposure
Digoxin
Mechanism
- Direct inhibition of Na+/K+ ATPase ⇒
- indirect inhibition of Na+/Ca2+ exchanger
- ^^ [Ca2+]i ⇒ positive inotropy
- Stimulates Vagus Nerve ⇒ reduced HR
Digoxin
Clinical Use
- HF
- increased Contractility
- A.Fib
- reduced conduction at AV node and SA node depression
Digoxin
Toxicity
- Cholinergic
- N/V/D
- Blurry yellow vision
- Arrhythmias
- AV block
- Hyperkalemia (poor prognostic)
- Toxic factors
- Renal Failure (reduced excretion)
- hypokalemia (binds Na+/K+ ATPase
- Verapamil/amidarone/quinidine (reduced clearance, displaces dig binding
Digoxin
Antidote
- Slowly normalize K+
- Cardiac Pacer
- Anti-Digoxin Fab fragments
- Mg2+
Lovastatin
Mechanism
- Inhibits conversion of HMG-CoA to mevalonate
- a cholesterol precurso
- Reduced mortality in CAD patients
Pravastatin
Mechanism
- Inhibits conversion of HMG-CoA to mevalonate
- a cholesterol precurso
- Reduced mortality in CAD patients
Simvastatin
Mechanism
- Inhibits conversion of HMG-CoA to mevalonate
- a cholesterol precurso
- Reduced mortality in CAD patients
Atorvastatin
Mechanism
- Inhibits conversion of HMG-CoA to mevalonate
- a cholesterol precurso
- Reduced mortality in CAD patients
Rosuvastatin
Mechanism
- Inhibits conversion of HMG-CoA to mevalonate
- a cholesterol precurso
- Reduced mortality in CAD patients
Lovastatin
Clinical Use
- vvv - LDL
- ^ - HDL
- v - Triglycerides
Pravastatin
Clinical Use
- vvv - LDL
- ^ - HDL
- v - Triglycerides
Simvastatin
Clinical Use
- vvv - LDL
- ^ - HDL
- v - Triglycerides
Atorvastatin
Clinical Use
- vvv - LDL
- ^ - HDL
- v - Triglycerides
Rosuvastatin
Clinical Use
- vvv - LDL
- ^ - HDL
- v - Triglycerides
Lovastatin
Toxicity
- Hepatotoxicity (more with Low LFTs)
- Myopathy (esp w/ fibrates or Niacin)
Pravastatin
Toxicity
- Hepatotoxicity (more with Low LFTs)
- Myopathy (esp w/ fibrates or Niacin)
Simvastatin
Toxicity
- Hepatotoxicity (more with Low LFTs)
- Myopathy (esp w/ fibrates or Niacin)
Atorvastatin
Toxicity
- Hepatotoxicity (more with Low LFTs)
- Myopathy (esp w/ fibrates or Niacin)
Rosuvastatin
Toxicity
- Hepatotoxicity (more with Low LFTs)
- Myopathy (esp w/ fibrates or Niacin)
Cholestyramine
Mechanism
Bile Acid Resin
- Prevents intestinal reabsorption of bile acids
- Liver must use cholesterol to make more
Colestipol
Mechanism
Bile Acid Resin
- Prevents intestinal reabsorption of bile acids
- Liver must use cholesterol to make more
Colesevelam
Mechanism
Bile Acid Resin
- Prevents intestinal reabsorption of bile acids
- Liver must use cholesterol to make more
Cholestryramine
Clinical Use
- vv - LDL
- slightly ^ - HDL
- slightly ^ - Triglycerides
Cholestipol
Clinical Use
- vv - LDL
- slightly ^ - HDL
- slightly ^ - Triglycerides
Cholesevelam
Clinical Use
- vv - LDL
- slightly ^ - HDL
- slightly ^ - Triglycerides
Cholestyramine
Toxicity
- GI Upset
- Reduced absorption of other drugs & fat soluble vitamins
Cholestipol
Toxicity
- GI Upset
- Reduced absorption of other drugs & fat soluble vitamins
Colesevelam
Toxicity
- GI Upset
- Reduced absorption of other drugs & fat soluble vitamins
Ezetimibe
Mechanism
- Prevents Cholesterol absorption at small intestine brush border
Ezetimibe
Clinical Use
- vv - LDL
- minimal HDL/Triglyceride change
Ezetimibe
Toxicity
- Rare
- elevated LFTs
- Diarrhea
Gemfibrozil
Mechanism
- Upregulate LPL →^^ TG clearance
- Activates PPAR-a to induce HDL synthesis
Clofibrate
Mechanism
- Upregulate LPL →^^ TG clearance
- Activates PPAR-a to induce HDL synthesis
Bezafibrate
Mechanism
- Upregulate LPL →^^ TG clearance
- Activates PPAR-a to induce HDL synthesis
Fenofibrate
Mechanism
- Upregulate LPL →^^ TG clearance
- Activates PPAR-a to induce HDL synthesis
Fenofibrate
Mechanism
- Upregulate LPL →^^ TG clearance
- Activates PPAR-a to induce HDL synthesis
Class that:
- Upregulate LPL →^^ TG clearance
- Activates PPAR-a to induce HDL synthesis
Drugs in that Class
Fibrates
Gemfibrozil
Clofibrate
Bezafibrate
Fenofibrate
Gemfibrozil
Toxicity
- Myopathy (increased w/ statins)
- Cholesterol Gallstones
Clofibrate
Toxicity
- Myopathy (increased w/ statins)
- Cholesterol Gallstones
Bezafibrate
Toxicity
- Myopathy (increased w/ statins)
- Cholesterol Gallstones
Fenofibrate
Toxicity
- Myopathy (increased w/ statins)
- Cholesterol Gallstones
Niacin
Mechanism
Vitamin B3
- Inhibits Lipolysis (hormonse sensitive lipase) in adipose
- Reduces hepatice VLDL synthesis
Niacin
Clinical Use
- vv - LDL
- ^^ - HDL
- v - Triglycerides
Niacin
Toxicity
- Red, flushed face (reduced by NSAID/ long term use)
- Hyperglycemia
- Hyperuricemia
Primary (Essential) Hypertension
Treatment
- Thiazide diuretics
- ACE inhibitors
- Angiotensis II receptor blockers
- dihydropyridine Ca2+ channel blockers
Hypertension with Heart Failure
Treatment
- Diuretics
- ACE inhibitors
- ARBs
- Beta-blockers (compensated HF)
- Aldosterone antagonists
Hypertension w/ Diabetes Mellitus
Treatment
- ACE inhibitors
- ARBs
- Ca2+ channel blockers
- Thiazide diuretics
- Beta-blockers
Hypertension in Pregnancy
Treatment
- Hydralazine
- Labetalol
- Methyldopa
- Nifedipine
Anti-Arrhythmics
Class I
Mechanism
Sodium Channel Blocker
- slows or blocks conduction
- reduced slopw of phase 0 depolerization
- State dependent ( selectivly depress tissue that is frequently depolarized, ie. tachycardic)
Quinidine
Mechanism
- Class Ia anti-arrhythmic
- Increases AP duration
- Increases ERP in ventricular AP
- Prolongs QT interval
Procainamide
Mechanism
- Class Ia anti-arrhythmic
- Increases AP duration
- Increases ERP in ventricular AP
- Prolongs QT interval
Disopyramide
Mechanism
- Class Ia anti-arrhythmic
- Increases AP duration
- Increases ERP in ventricular AP
- Prolongs QT interval
Quinidine
Clinical Use
- Class Ia anti-arrhythmic
- Both Atrial and Ventricular arrhythmias
- especially re-entrant and ectopic SVT and VT
Procainamide
Clinical Use
- Class Ia anti-arrhythmic
- Both Atrial and Ventricular arrhythmias
- especially re-entrant and ectopic SVT and VT
Disopyramide
Clinical Use
- Class Ia anti-arrhythmic
- Both Atrial and Ventricular arrhythmias
- especially re-entrant and ectopic SVT and VT
Quinidine
Toxicity
- Class Ia anti-arrhythmic
- Cinchonism (quinine toxicity)
- Headache, tinnitus
- thrombocytopenia
- TdP due to QT prolongation
Procainamide
Toxicity
- Class Ia anti-arrhythmic
- Reversible SLE -like symptoms
- thrombocytopenia
- TdP due to QT prolongation
Disopyramide
Toxicity
- Class Ia anti-arrhythmia
- Heart failure
- thrombocytopenia
- TdP due to QT prolongation